(Q38228098)

31 August 2017

title

Imaging the role of amyloid in PD dementia and dementia with Lewy bodies (English)

1 reference

31 August 2017

0 references

Stephen N Gomperts

1

1 reference

31 August 2017

publication date

1 August 2014

1 reference

Current Neurology and Neuroscience Reports

31 August 2017

published in

1 reference

31 August 2017

volume

14

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

472

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-014-0472-6

31 August 2017

exact match

0 references

cites work

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

PET of brain amyloid and tau in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging amyloid deposition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

APOE modifies the association between Aβ load and cognition in cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Aβ amyloid, cognition, and APOE genotype in healthy older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Meta-analysis of amyloid-cognition relations in cognitively normal older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Relation between clinical characteristics of Parkinson's disease and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Relationship of motor symptoms to intellectual deficits in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cholinergic dysfunction in diseases with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The many faces of alpha-synuclein mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Neuropathology of dementia in a large cohort of patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Neuropathologic substrates of Parkinson disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The neurobiological basis of cognitive impairment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Neuropathology of Lewy body disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Parkinson disease with dementia: comparing patients with and without Alzheimer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

A clinico-pathological study of subtypes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Differences in neuropathologic characteristics across the Lewy body dementia spectrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Dementia with Lewy bodies: neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid imaging of Lewy body-associated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Brain amyloid and cognition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

[11C]PIB binding in Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Multimodality imaging characteristics of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Impact of molecular imaging on the diagnostic process in a memory clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Changes in motor subtype and risk for incident dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

CSF Aβ42 predicts early-onset dementia in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Interaction between pathogenic proteins in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Biomarkers in dementia with Lewy bodies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

What can biomarkers tell us about cognition in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Tau pathology and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-014-0472-6

Predictors of survival in dementia with lewy bodies and Parkinson dementia

21 January 2018

1 reference

12 December 2020

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

1 reference

12 December 2020

Dementia with Lewy bodies

1 reference

12 December 2020

Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.

1 reference

12 December 2020

The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

1 reference

12 December 2020

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

1 reference

12 December 2020

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

1 reference

12 December 2020

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

12 December 2020

Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease

1 reference

12 December 2020

Cortical Lewy body pathology in the diagnosis of dementia.

1 reference

12 December 2020

PET imaging of neuropathology in tauopathies: progressive supranuclear palsy

1 reference

12 December 2020

Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes

1 reference

12 December 2020

Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers

1 reference

12 December 2020

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis

1 reference

12 December 2020

A Population-Based Investigation of Parkinson's Disease With and Without Dementia

1 reference

12 December 2020

A highly selective and specific PET tracer for imaging of tau pathologies

1 reference

12 December 2020

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

1 reference

12 December 2020

10.1007/S11910-014-0472-6

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1044578427

0 references

1 reference